Completed PHASE1 INTERVENTIONAL 2-arm NCT02319772

A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430

A Phase 1 Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BCX4430 Administered Via Intramuscular Injection (IM) in Healthy Subjects

Sponsor: BioCryst Pharmaceuticals

Conditions Ebola Virus Infection Filovirus Infections

Interventions BCX4430 Placebo

Updated 6 times since 2017 Last updated: Jul 6, 2016 Started: Dec 31, 2014 Primary completion: Mar 31, 2016 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Ebola Virus Infection and Filovirus Infections, this trial is completed. The trial is conducted by BioCryst Pharmaceuticals and has accumulated 6 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioCryst Pharmaceuticals
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: BioCryst Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ruddington, United Kingdom